PCIDB

KNApSAcK Metabolite C00009392

Metabolite

KNApSAcK Entry

id C00009392
Name Glycitein / 7,4'-Dihydroxy-6-methoxyisoflavone
CAS RN 40957-83-3
Standard InChI InChI=1S/C16H12O5/c1-20-15-6-11-14(7-13(15)18)21-8-12(16(11)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3
Standard InChI (Main Layer) InChI=1S/C16H12O5/c1-20-15-6-11-14(7-13(15)18)21-8-12(16(11)19)9-2-4-10(17)5-3-9/h2-8,17-18H,1H3

Cluster

Phytochemical cluster No. 15
KCF-S cluster No. 3

Link

ChEMBL

By standard InChI CHEMBL513024
By standard InChI Main Layer CHEMBL513024

KEGG

By LinkDB C14536

CTD

By CAS RN C086566

Human Protein / Gene in interaction

2 ChEMBL Protein in interactions

accession description class description compound assay ID (# of activities) # of diseases
(OMIM / KEGG)
P47989 Xanthine dehydrogenase/oxidase Oxidoreductase CHEMBL513024 CHEMBL991725 (1) CHEMBL990777 (1)
1 / 1
P03372 Estrogen receptor NR3A1 CHEMBL513024 CHEMBL999946 (1)
1 / 1

CTD interaction (54)

compound gene gene name gene description interaction interaction type form reference
pmid
C086566 19 ABCA1
ABC-1
ABC1
CERP
HDLDT1
TGD
ATP-binding cassette, sub-family A (ABC1), member 1 [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of ABCA1 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 119 ADD2
ADDB
adducin 2 (beta) [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of ADD2 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 396 ARHGDIA
GDIA1
NPHS8
RHOGDI
RHOGDI-1
Rho GDP dissociation inhibitor (GDI) alpha glycitein results in decreased expression of ARHGDIA mRNA decreases expression
mRNA 15757668
C086566 23545 ATP6V0A2
A2
ARCL
ARCL2A
ATP6A2
ATP6N1D
J6B7
RTF
STV1
TJ6
TJ6M
TJ6S
VPH1
WSS
ATPase, H+ transporting, lysosomal V0 subunit a2 (EC:3.6.3.6) [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of ATP6V0A2 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 11177 BAZ1A
ACF1
WALp1
WCRF180
hACF1
bromodomain adjacent to zinc finger domain, 1A [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of BAZ1A mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 890 CCNA2
CCN1
CCNA
cyclin A2 glycitein results in decreased expression of CCNA2 decreases expression
21161820
C086566 595 CCND1
BCL1
D11S287E
PRAD1
U21B31
cyclin D1 glycitein results in increased expression of CCND1 mRNA increases expression
mRNA 19800779
C086566 1019 CDK4
CMM3
PSK-J3
cyclin-dependent kinase 4 (EC:2.7.11.22) glycitein results in decreased activity of CDK4 protein decreases activity
protein 21161820
C086566 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) ESR2 affects the reaction [glycitein results in increased expression of CDKN1A] affects reaction
/ increases expression
21161820
C086566 1026 CDKN1A
CAP20
CDKN1
CIP1
MDA-6
P21
SDI1
WAF1
p21CIP1
cyclin-dependent kinase inhibitor 1A (p21, Cip1) glycitein results in increased expression of CDKN1A increases expression
21161820
C086566 1795 DOCK3
MOCA
PBP
dedicator of cytokinesis 3 [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of DOCK3 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 2041 EPHA1
EPH
EPHT
EPHT1
EPH receptor A1 (EC:2.7.10.1) [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of EPHA1 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 83715 ESPN
DFNB36
espin [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of ESPN mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 glycitein binds to ESR1 protein affects binding
protein 14579009
C086566 2099 ESR1
ER
ESR
ESRA
ESTRR
Era
NR3A1
estrogen receptor 1 glycitein inhibits the reaction [Estradiol binds to ESR1 protein] affects binding
/ decreases reaction
protein 14579009
C086566 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) ESR2 affects the reaction [glycitein results in increased expression of CDKN1A] affects reaction
/ increases expression
21161820
C086566 2100 ESR2
ER-BETA
ESR-BETA
ESRB
ESTRB
Erb
NR3A2
estrogen receptor 2 (ER beta) ESR2 affects the susceptibility to glycitein affects response to substance
21161820
C086566 56776 FMN2
formin 2 [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of FMN2 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 7866 IFRD2
IFNRP
SKMc15
SM15
interferon-related developmental regulator 2 [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of IFRD2 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 26145 IRF2BP1
interferon regulatory factor 2 binding protein 1 [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of IRF2BP1 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 3725 JUN
AP-1
AP1
c-Jun
jun proto-oncogene glycitein results in increased activity of JUN protein increases activity
protein 17088408
C086566 26251 KCNG2
KCNF2
KV6.2
potassium voltage-gated channel, subfamily G, member 2 [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of KCNG2 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) glycitein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein] decreases reaction
/ increases phosphorylation
protein 20188714
C086566 5594 MAPK1
ERK
ERK2
ERT1
MAPK2
P42MAPK
PRKM1
PRKM2
p38
p40
p41
p41mapk
mitogen-activated protein kinase 1 (EC:2.7.11.24) glycitein results in increased phosphorylation of MAPK1 protein increases phosphorylation
protein 17088408
C086566 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) glycitein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein] decreases reaction
/ increases phosphorylation
protein 20188714
C086566 5595 MAPK3
ERK-1
ERK1
ERT2
HS44KDAP
HUMKER1A
P44ERK1
P44MAPK
PRKM3
p44-ERK1
p44-MAPK
mitogen-activated protein kinase 3 (EC:2.7.11.24) glycitein results in increased phosphorylation of MAPK3 protein increases phosphorylation
protein 17088408
C086566 4314 MMP3
CHDS6
MMP-3
SL-1
STMY
STMY1
STR1
matrix metallopeptidase 3 (stromelysin 1, progelatinase) (EC:3.4.24.17) glycitein results in decreased expression of MMP3 mRNA decreases expression
mRNA 20188714
C086566 4314 MMP3
CHDS6
MMP-3
SL-1
STMY
STMY1
STR1
matrix metallopeptidase 3 (stromelysin 1, progelatinase) (EC:3.4.24.17) glycitein results in decreased expression of MMP3 protein decreases expression
protein 20188714
C086566 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) glycitein inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MMP9 protein] decreases reaction
/ increases secretion
protein 20188714
C086566 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) glycitein results in decreased expression of MMP9 mRNA decreases expression
mRNA 20188714
C086566 4318 MMP9
CLG4B
GELB
MANDP2
MMP-9
matrix metallopeptidase 9 (gelatinase B, 92kDa gelatinase, 92kDa type IV collagenase) (EC:3.4.24.35) glycitein results in decreased expression of MMP9 protein decreases expression
protein 20188714
C086566 8204 NRIP1
RIP140
nuclear receptor interacting protein 1 glycitein results in increased expression of NRIP1 mRNA increases expression
mRNA 15757668
C086566 56944 OLFML3
HNOEL-iso
OLF44
olfactomedin-like 3 [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of OLFML3 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 5111 PCNA
proliferating cell nuclear antigen glycitein results in decreased expression of PCNA decreases expression
21161820
C086566 64236 PDLIM2
MYSTIQUE
SLIM
PDZ and LIM domain 2 (mystique) [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of PDLIM2 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 5411 PNN
DRS
DRSP
SDK3
memA
pinin, desmosome associated protein [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of PNN mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 5458 POU4F2
BRN3.2
BRN3B
Brn-3b
POU class 4 homeobox 2 [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of POU4F2 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 6197 RPS6KA3
CLS
HU-3
ISPK-1
MAPKAPK1B
MRX19
RSK
RSK2
S6K-alpha3
p90-RSK2
pp90RSK2
ribosomal protein S6 kinase, 90kDa, polypeptide 3 (EC:2.7.11.1) glycitein results in increased expression of RPS6KA3 mRNA increases expression
mRNA 15757668
C086566 81537 SGPP1
SPPase1
sphingosine-1-phosphate phosphatase 1 [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of SGPP1 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 6558 SLC12A2
BSC
BSC2
NKCC1
solute carrier family 12 (sodium/potassium/chloride transporter), member 2 glycitein results in decreased expression of SLC12A2 mRNA decreases expression
mRNA 15757668
C086566 6667 SP1
Sp1 transcription factor glycitein promotes the reaction [SP1 protein binds to VDR promoter] affects binding
/ increases reaction
protein 17088408
C086566 6667 SP1
Sp1 transcription factor glycitein results in increased activity of SP1 protein increases activity
protein 17088408
C086566 6667 SP1
Sp1 transcription factor U 0126 inhibits the reaction [glycitein results in increased activity of SP1 protein] decreases reaction
/ increases activity
protein 17088408
C086566 6781 STC1
STC
stanniocalcin 1 [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of STC1 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 6870 TACR3
HH11
NK-3R
NK3R
NKR
TAC3RL
tachykinin receptor 3 [Genistein co-treated with daidzein co-treated with glycitein] results in increased expression of TACR3 mRNA affects cotreatment
/ increases expression
mRNA 16963248
C086566 7130 TNFAIP6
TSG-6
TSG6
tumor necrosis factor, alpha-induced protein 6 [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of TNFAIP6 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 7157 TP53
BCC7
LFS1
P53
TRP53
tumor protein p53 glycitein results in increased expression of TP53 protein increases expression
protein 19800779
C086566 9537 TP53I11
PIG11
tumor protein p53 inducible protein 11 glycitein results in decreased expression of TP53I11 mRNA decreases expression
mRNA 15757668
C086566 7345 UCHL1
NDGOA
PARK5
PGP_9.5
PGP9.5
PGP95
Uch-L1
ubiquitin carboxyl-terminal esterase L1 (ubiquitin thiolesterase) (EC:3.4.19.12) [Genistein co-treated with daidzein co-treated with glycitein] results in decreased expression of UCHL1 mRNA affects cotreatment
/ decreases expression
mRNA 16963248
C086566 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor fulvestrant inhibits the reaction [glycitein results in increased expression of VDR protein] decreases reaction
/ increases expression
protein 17088408
C086566 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor glycitein promotes the reaction [SP1 protein binds to VDR promoter] affects binding
/ increases reaction
promoter 17088408
C086566 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor glycitein results in increased expression of VDR mRNA increases expression
mRNA 17088408
C086566 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor glycitein results in increased expression of VDR protein increases expression
protein 17088408
C086566 7421 VDR
NR1I1
vitamin D (1,25- dihydroxyvitamin D3) receptor U 0126 inhibits the reaction [glycitein results in increased expression of VDR protein] decreases reaction
/ increases expression
protein 17088408

Related Disease

Diseases related to proteins in ChEMBL interactions

OMIM (2)

OMIM preferred title UniProt
#615363 Estrogen resistance; estrr P03372
#278300 Xanthinuria, type i P47989

KEGG DISEASE (2)

KEGG disease name UniProt
H00026 Endometrial Cancer P03372 (marker)
H00192 Xanthinuria P47989 (related)

Diseases related to CTD interactions

4 disease from interactions of metabolites

MeSH disease OMIM compound disease name evidence type reference
pmid
D001254 C086566 Astrocytoma therapeutic
20188714
D009361 C086566 Neoplasm Invasiveness therapeutic
20188714
D019636 C086566 Neurodegenerative Diseases therapeutic
16122394
D010243 C086566 Paralysis therapeutic
16122394